SITE014-0419

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-08-10

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-25 (study day 39); relationship: not assessed

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-14 (study day 58); relationship: not assessed

severe serious assessed

Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-10-27 (study day 71); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-11-09 (study day 84); relationship: not assessed

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-12-22 (study day 127); relationship: N

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-01-12 (study day 148); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-28 (study day 164); relationship: not assessed

Data queries

No data queries.